Pravachol (pravastatin sodium)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 ADVERSE REACTIONS Postmarketing Experience Musculoskeletal: addition of tendon disorder, polymyositis ...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts